A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Allergan
- Target Recruit Count
- 138
- Registration Number
- NCT00395057
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2008-01-07
- Lead Sponsor
- Allergan
- Target Recruit Count
- 330
- Registration Number
- NCT00381719
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 2
- Registration Number
- NCT00380783
A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2008-08-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 26
- Registration Number
- NCT00363714
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 2
- Registration Number
- NCT00343187
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 5
- Registration Number
- NCT00333996
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 229
- Registration Number
- NCT00333814
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 541
- Registration Number
- NCT00332072
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 445
- Registration Number
- NCT00332059
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 520
- Registration Number
- NCT00332540
© Copyright 2024. All Rights Reserved by MedPath